Latest Updates
November 2008 Combination Trial Updates and Additions

Protocol ID	Trial Title
CDR0000335292; CALGB-90206; CAN-NCIC-CLB-90206; ECOG-CALGB-90206; NCT00072046	A Two-Arm, Phase III Trial of Bevacizumab in Combination with Interferon Alfa-2b in Patients with Advanced Renal Carcinoma
BO17705; NCT00738530	A Randomized Phase III Trial Of Interferon Alfa-2B or Interferon Alfa-2B Plus Bevacizumab in Patients With Advanced Renal Carcinoma
A6181087; SUN1087; NCT00457392	A Multicenter, Randomized, Double-Blind, Controlled Phase 3, Efficacy And Safety Study Of Sunitinib (SU011248) In Patients With Advanced/Metastatic Non-Small Cell Lung Cancer Treated With Erlotinib
YMB 1000-015; NCT00493857	A Phase II Open-Label, 2-Cohort Study of Nimotuzumab 400 mg Weekly Plus Irinotecan (Cohort 1) and Nimotuzumab 400 mg Every 2 Weeks Plus Irinotecan (Cohort 2) in Patients With Irinotecan-Refractory Metastatic Colorectal Cancer
OSAG101-PCS07; NCT00561990	A Randomized, Multicenter, Phase IIb/IIIa Study of Gemcitabine and the Monoclonal Antibody Nimotuzumab (OSAG 101) Versus Gemcitabine and Placebo for the Treatment of Chemotherapy-Naïve Patients with Locally Advanced Or Metastatic Pancreatic Cancer
BO18192; NCT00556712	A Randomized, Double-blind Study to Evaluate the Effect of Tarceva or Placebo Following Platinum-Based Chemotherapy on Overall Survival and Disease Progression in Patients With Advanced, Recurrent or Metastatic Non-small Cell Lung Cancer (NSCLC) Without Disease Progression or Unacceptable Toxicity